USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Recent Technological Advances across AI-Enabled Drug Discovery, Neurodegenerative Disease Management, and Treatment of Metabolic Diseases
Life Science, Health & Wellness Technology Opportunity Engine
25-Jul-2025
Global
Technology Research
D759-00-4I-00-00
HC_2025_33677
$950.00
Special Price $855.00 save 10 %
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses insights across advances in targeted neurological therapies, cancer treatments, and AI-powered drug development. The TOE also features innovators for treatment of metabolic diseases such as obesity and heart failure.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: ?-synuclein, Parkinson’s disease, Silica-based topical delivery, sustained release, drug delivery, blood brain barrier delivery, bispecific antibody, neurodegenerative disease, peptide-based drug delivery, biomacromolecules, cerebral malformations, cavernous malformations, neurodegenerative diseases, Alzheimer’s disease, brain tumor, cancer, chemoproteomics, proteome, apoptosis, autophagy, fibrosis, cardioprotection, heart attack, drug discovery, small molecules, agentic AI, real-world patient data, clinical research, drug development, federated learning, protein engineering, generative AI, synthetic biology, organoid, oncology, immune-oncology, organoid screening, drug screening, in-silico models, multi-scale foundation models, GLP-1, obesity, CAR-T cell therapy, tumor, axonal degeneration, tissue bioprinting, regeneration, hypophosphatasia, neutrophil, macrophage, inflammation, glycol-therapeutics, hyperphosphatemia
Silica-based Topical Delivery Platform For Sustained Release At Targeted Location
Igf1r Targeting BBB Shuttle To Enable Delivery Across Blood-Brain Barrier
Peptide-Based Technology To Facilitate Drug Delivery Across Blood-Brain Barrier
Technology platform enabling delivery of biomacromolecules across blood-brain barrier
Safer Way To Stop The Growth And Formation Of Cerebral Cavernous Malformations
Chemoproteomics-Driven Covalent Ligand Discovery Platform for Targeting the Undruggable Proteome
A Next-Generation Drug Discovery Platform Combining Native-State Biology with High-Resolution Binding Precision
Agentic AI Navigator for Precision Medicine and Biomarker Discovery
Generative AI-Driven Platform for Functional Protein Design and Optimization
High-Throughput Patient-Derived Organoid Platform for Predictive Oncology Drug Screening and Translational Research
Multiscale AI Foundation Model Platform for Simulating and Predicting Complex Biological Systems In Silico
VRB-101— GLP-1 Receptor Agonist For Obesity
SARM1 – Peripheral Restricted Inhibitor Of Axonal Degeneration
Bioprinted Tissue Therapeutic Platform Regenerative Medicine
ALE1 Orally Active Therapeutic Candidate For Hypophosphatasia
AVD-104: To Suppress Neutrophil And Macrophage Activation And Lower Inflammatory Mediators
AP306 The Treatment of Autosomal Dominant Polycystic Kidney Disease ADPKD
Speak directly with our analytics experts for tailored recommendations.
Recent related In Vitro Diagnostics (IVD) research
21 Jul 2026 | Global | Market Research
Point-of-Care Testing Market, Global, 2024–2031
The global POCT market is rapidly evolving from standalone rapid diagnostics to connected, AI-enabled clinical intelligence ecosystems that support decentralized healthcare delivery. Growth is driven by the increasing demand for faster clinical decision-making, early disease detection, personalized ...
17 Jul 2026 | Global | Technology Research
Innovations and Growth Opportunities in AI-Driven Drug Discovery, Precision Diagnostics, Advanced Biologics, and Next-generation Vaccines
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and autoimmune disorders, metabolic and age...
08 Jul 2026 | Global | Technology Research
Precision Obesity Management: AI-Guided Metabolic Modulation
The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and envir...
25 Jun 2026 | Global | Technology Research
Quantum Sensors Transitioning from Lab to Industry: Ultra-Precision Measurement for Healthcare, Defense, and Manufacturing
Quantum sensing is transitioning from laboratory research to industrial deployment, driven by the need for ultra-precise, reliable measurement in high-impact sectors such as healthcare, defense, and advanced manufacturing. This shift reflects a broader move from controlled, research-grade environmen...
22 Jun 2026 | Global | Market Research
Growth Opportunities, Global Life Sciences LIMS Market, Forecast to 2031
The global life sciences laboratory information management systems (LIMS) industry is forecast to grow from 2026 to 2031 at a CAGR of 8.5%, driven by the increasing need for laboratory automation, regulatory compliance, and cloud-based solutions.
Leading players in the global life sciences L...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: α-synuclein, Parkinson’s disease, Silica-based topical delivery, sustained release, drug delivery, blood brain barrier delivery, bispecific antibody, neurodegenerative disease, peptide-based drug delivery, biomacromolecules, cerebral malformations, cavernous malformations, neurodegenerative diseases, Alzheimer’s disease, brain tumor, cancer, chemoproteomics, proteome, apoptosis, autophagy, fibrosis, cardioprotection, heart attack, drug discovery, small molecules, agentic AI, real-world patient data, clinical research, drug development, federated learning, protein engineering, generative AI, synthetic biology, organoid, oncology, immune-oncology, organoid screening, drug screening, in-silico models, multi-scale foundation models, GLP-1, obesity, CAR-T cell therapy, tumor, axonal degeneration, tissue bioprinting, regeneration, hypophosphatasia, neutrophil, macrophage, inflammation, glycol-therapeutics, hyperphosphatemia
| Deliverable Type | Technology Research |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | AI drug discovery market |
| Keyword 2 | biopharma AI solutions |
| Keyword 3 | healthcare technology trends |
| Podcast | No |
| Predecessor | D759-00-4H-00-00 |
| WIP Number | D759-00-4I-00-00 |